Cargando…

Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels

BACKGROUND: It is not well defined whether Guillain–Barré syndrome (GBS) patients with elevated serum creatine kinase (CK) levels have characteristic clinical features and are related to the subgroups of GBS. METHODS: We retrospectively studied 51 consecutive patients with GBS, who visited our hospi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosokawa, Takafumi, Nakajima, Hideto, Sawai, Taiki, Nakamura, Yoshitsugu, Sano, Eri, Tsukahara, Akihiro, Unoda, Kiichi, Ishida, Shimon, Sakane, Sadaki, Kimura, Fumiharu, Arawaka, Shigeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251688/
https://www.ncbi.nlm.nih.gov/pubmed/32460711
http://dx.doi.org/10.1186/s12883-020-01796-z
_version_ 1783539005745266688
author Hosokawa, Takafumi
Nakajima, Hideto
Sawai, Taiki
Nakamura, Yoshitsugu
Sano, Eri
Tsukahara, Akihiro
Unoda, Kiichi
Ishida, Shimon
Sakane, Sadaki
Kimura, Fumiharu
Arawaka, Shigeki
author_facet Hosokawa, Takafumi
Nakajima, Hideto
Sawai, Taiki
Nakamura, Yoshitsugu
Sano, Eri
Tsukahara, Akihiro
Unoda, Kiichi
Ishida, Shimon
Sakane, Sadaki
Kimura, Fumiharu
Arawaka, Shigeki
author_sort Hosokawa, Takafumi
collection PubMed
description BACKGROUND: It is not well defined whether Guillain–Barré syndrome (GBS) patients with elevated serum creatine kinase (CK) levels have characteristic clinical features and are related to the subgroups of GBS. METHODS: We retrospectively studied 51 consecutive patients with GBS, who visited our hospital, and compared clinical, laboratory and electrophysiological findings between patients with and without elevated CK levels. RESULTS: Of 51 patients, 14 patients (27%) showed an elevation of serum CK levels. When compared with patients with the normal CK levels, the ratios of male, antecedent infections, and anti-GM1 antibody positivity were significantly higher in patients with elevated CK levels. The ratios of hypoesthesia, cranial nerve involvement, and urinary retention were significantly less in patients with elevated CK levels. There were no significant differences in disability at peak between two groups. In the electrophysiological examination, sensory nerve abnormalities were not observed. Although some patients with elevated CK levels showed prolongation of distal motor latencies (DMLs) and increase of durations in the initial examination, development of the prolongation of DMLs and increase of durations was not observed in the follow-up examinations. The findings were consistent with acute motor axonal neuropathy (AMAN) with reversible conduction failure (RCF) but not acute inflammatory demyelinating polyneuropathy (AIDP). CONCLUSIONS: The results suggest that the GBS patients with elevated CK levels represent not a group of AIDP but a group of AMAN with axonal degeneration or RCF even though the initial electrophysiological examination shows AIDP pattern.
format Online
Article
Text
id pubmed-7251688
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72516882020-06-04 Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels Hosokawa, Takafumi Nakajima, Hideto Sawai, Taiki Nakamura, Yoshitsugu Sano, Eri Tsukahara, Akihiro Unoda, Kiichi Ishida, Shimon Sakane, Sadaki Kimura, Fumiharu Arawaka, Shigeki BMC Neurol Research Article BACKGROUND: It is not well defined whether Guillain–Barré syndrome (GBS) patients with elevated serum creatine kinase (CK) levels have characteristic clinical features and are related to the subgroups of GBS. METHODS: We retrospectively studied 51 consecutive patients with GBS, who visited our hospital, and compared clinical, laboratory and electrophysiological findings between patients with and without elevated CK levels. RESULTS: Of 51 patients, 14 patients (27%) showed an elevation of serum CK levels. When compared with patients with the normal CK levels, the ratios of male, antecedent infections, and anti-GM1 antibody positivity were significantly higher in patients with elevated CK levels. The ratios of hypoesthesia, cranial nerve involvement, and urinary retention were significantly less in patients with elevated CK levels. There were no significant differences in disability at peak between two groups. In the electrophysiological examination, sensory nerve abnormalities were not observed. Although some patients with elevated CK levels showed prolongation of distal motor latencies (DMLs) and increase of durations in the initial examination, development of the prolongation of DMLs and increase of durations was not observed in the follow-up examinations. The findings were consistent with acute motor axonal neuropathy (AMAN) with reversible conduction failure (RCF) but not acute inflammatory demyelinating polyneuropathy (AIDP). CONCLUSIONS: The results suggest that the GBS patients with elevated CK levels represent not a group of AIDP but a group of AMAN with axonal degeneration or RCF even though the initial electrophysiological examination shows AIDP pattern. BioMed Central 2020-05-27 /pmc/articles/PMC7251688/ /pubmed/32460711 http://dx.doi.org/10.1186/s12883-020-01796-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Hosokawa, Takafumi
Nakajima, Hideto
Sawai, Taiki
Nakamura, Yoshitsugu
Sano, Eri
Tsukahara, Akihiro
Unoda, Kiichi
Ishida, Shimon
Sakane, Sadaki
Kimura, Fumiharu
Arawaka, Shigeki
Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels
title Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels
title_full Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels
title_fullStr Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels
title_full_unstemmed Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels
title_short Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels
title_sort clinical features of guillain–barré syndrome patients with elevated serum creatine kinase levels
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251688/
https://www.ncbi.nlm.nih.gov/pubmed/32460711
http://dx.doi.org/10.1186/s12883-020-01796-z
work_keys_str_mv AT hosokawatakafumi clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels
AT nakajimahideto clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels
AT sawaitaiki clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels
AT nakamurayoshitsugu clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels
AT sanoeri clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels
AT tsukaharaakihiro clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels
AT unodakiichi clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels
AT ishidashimon clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels
AT sakanesadaki clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels
AT kimurafumiharu clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels
AT arawakashigeki clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels